Table 3 Outcome following induction therapy in pediatric acute myeloid leukemia cases.
Abbreviations: AML 2012, double induction regimen consisting of idarubicin (IDA) or mitoxantrone plus cytarabine based chemotherapy; KSBRM, idarubicin plus N4-behenoyl-1-β-D-arabinofuranosyl cytosine (BHAC) based chemotherapy; Responder, complete remission plus partial remission.